Published in J Neurosci on November 28, 2007
A molecular signature of depression in the amygdala. Am J Psychiatry (2009) 2.18
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med (2012) 1.97
The fibroblast growth factor family: neuromodulation of affective behavior. Neuron (2012) 1.80
REDD1 is essential for stress-induced synaptic loss and depressive behavior. Nat Med (2014) 1.77
Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry (2010) 1.66
Role of CRF receptor signaling in stress vulnerability, anxiety, and depression. Ann N Y Acad Sci (2009) 1.59
Coordinated messenger RNA/microRNA changes in fibroblasts of patients with major depression. Biol Psychiatry (2014) 1.54
Detecting disease-associated genes with confounding variable adjustment and the impact on genomic meta-analysis: with application to major depressive disorder. BMC Bioinformatics (2012) 1.46
Decreased SGK1 Expression and Function Contributes to Behavioral Deficits Induced by Traumatic Stress. PLoS Biol (2015) 1.42
Epigenetic and inflammatory marker profiles associated with depression in a community-based epidemiologic sample. Psychol Med (2010) 1.38
Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets (2013) 1.26
Gene expression studies in major depression. Curr Psychiatry Rep (2010) 1.17
Antidepressant effects of fibroblast growth factor-2 in behavioral and cellular models of depression. Biol Psychiatry (2012) 1.14
Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry (2012) 1.08
Glial and glutamatergic markers in depression, alcoholism, and their comorbidity. J Affect Disord (2010) 1.06
Cell atrophy and loss in depression: reversal by antidepressant treatment. Curr Opin Cell Biol (2011) 1.01
Failure to mount adaptive responses to stress results in dysregulation and cell death in the midbrain raphe. J Neurosci (2008) 1.00
Blood-based gene expression profiles models for classification of subsyndromal symptomatic depression and major depressive disorder. PLoS One (2012) 0.99
The reduction of R1, a novel repressor protein for monoamine oxidase A, in major depressive disorder. Neuropsychopharmacology (2011) 0.95
Molecular pathway reconstruction and analysis of disturbed gene expression in depressed individuals who died by suicide. PLoS One (2012) 0.91
Is it really a matter of simple dualism? Corticotropin-releasing factor receptors in body and mental health. Front Endocrinol (Lausanne) (2013) 0.83
Acute and chronic stress differentially regulate cyclin-dependent kinase 5 in mouse brain: implications to glucocorticoid actions and major depression. Transl Psychiatry (2015) 0.83
Molecular and Genetic Characterization of Depression: Overlap with other Psychiatric Disorders and Aging. Mol Neuropsychiatry (2015) 0.81
DNA modification study of major depressive disorder: beyond locus-by-locus comparisons. Biol Psychiatry (2014) 0.81
cDNA microarray analysis of gene expression in the cerebral cortex and hippocampus of BALB/c mice subjected to chronic mild stress. Cell Mol Neurobiol (2010) 0.80
YY1 and FoxD3 regulate antiretroviral zinc finger protein OTK18 promoter activation induced by HIV-1 infection. J Neuroimmune Pharmacol (2008) 0.78
Effect of lamotrigine and carbamazepine on corticotropin-releasing factor-associated serotonergic transmission in rat dorsal raphe nucleus. Psychopharmacology (Berl) (2011) 0.77
Mood, stress and longevity: convergence on ANK3. Mol Psychiatry (2016) 0.76
BICC1 expression is elevated in depressed subjects and contributes to depressive behavior in rodents. Neuropsychopharmacology (2014) 0.76
Evidence revealing deregulation of the KLF11-MAO A pathway in association with chronic stress and depressive disorders. Neuropsychopharmacology (2014) 0.76
Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants. Curr Neuropharmacol (2017) 0.75
Systems Genomics Support for Immune and Inflammation Hypothesis of Depression. Curr Neuropharmacol (2016) 0.75
Whole-transcriptome brain expression and exon-usage profiling in major depression and suicide: evidence for altered glial, endothelial and ATPase activity. Mol Psychiatry (2016) 0.75
Sex-specific transcriptional signatures in human depression. Nat Med (2017) 0.75
Length of axons expressing the serotonin transporter in orbitofrontal cortex is lower with age in depression. Neuroscience (2017) 0.75
-Glial and stem cell expression of murine Fibroblast Growth Factor Receptor 1 in the embryonic and perinatal nervous system. PeerJ (2017) 0.75
Anatomical Organization of Urocortin 3-Synthesizing Neurons and Immunoreactive Terminals in the Central Nervous System of Non-Human Primates [Sapajus spp.]. Front Neuroanat (2017) 0.75
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry (1994) 48.75
Missing value estimation methods for DNA microarrays. Bioinformatics (2001) 20.84
Subgenual prefrontal cortex abnormalities in mood disorders. Nature (1997) 9.36
A neurotrophic model for stress-related mood disorders. Biol Psychiatry (2006) 8.97
Neurobiology of depression. Neuron (2002) 8.56
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci (2006) 8.24
Statistical tests for differential expression in cDNA microarray experiments. Genome Biol (2003) 7.65
The mesolimbic dopamine reward circuit in depression. Biol Psychiatry (2006) 7.62
A molecular and cellular theory of depression. Arch Gen Psychiatry (1997) 6.10
Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry (1999) 5.63
The many faces of CREB. Trends Neurosci (2005) 5.58
Improved statistical tests for differential gene expression by shrinking variance components estimates. Biostatistics (2005) 5.57
Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A (1996) 5.24
The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology (2000) 5.14
Hippocampal volume reduction in major depression. Am J Psychiatry (2000) 5.04
Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci (1999) 4.59
Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A (1998) 4.16
Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol (2001) 4.00
The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo. Cell (1989) 3.95
Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry (2004) 3.64
Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res (2007) 3.56
Five years on the wings of fork head. Mech Dev (1996) 3.47
The cellular neurobiology of depression. Nat Med (2001) 3.19
Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci (2001) 3.09
Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet (2000) 3.04
Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus (2006) 3.02
Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry (2001) 2.92
Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 2.83
Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry (1999) 2.78
Preclinical models: status of basic research in depression. Biol Psychiatry (2002) 2.76
The transcriptional control of trunk neural crest induction, survival, and delamination. Dev Cell (2005) 2.67
Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry (2001) 2.55
Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry (2002) 2.53
Depression: a case of neuronal life and death? Biol Psychiatry (2004) 2.45
Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A (2005) 2.38
Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex (2002) 2.31
Transformations for cDNA microarray data. Stat Appl Genet Mol Biol (2003) 2.23
Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci U S A (2004) 2.19
A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal. FASEB J (2006) 2.17
Validity of DSM-III-R diagnosis by psychological autopsy: a comparison with clinician ante-mortem diagnosis. Acta Psychiatr Scand (1996) 2.13
The winged-helix transcription factor FoxD3 is important for establishing the neural crest lineage and repressing melanogenesis in avian embryos. Development (2001) 2.02
Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport (1998) 2.00
A comparative review of estimates of the proportion unchanged genes and the false discovery rate. BMC Bioinformatics (2005) 2.00
The winged-helix transcription factor Foxd3 suppresses interneuron differentiation and promotes neural crest cell fate. Development (2001) 1.96
The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology (2002) 1.94
Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med (2004) 1.94
Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet (2000) 1.90
Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron (2003) 1.84
Volumetric analysis of the prefrontal cortex, amygdala, and hippocampus in major depression. Neuropsychopharmacology (2004) 1.82
The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry (2005) 1.81
RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. J Biol Chem (1999) 1.81
TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry (2006) 1.67
Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci (2006) 1.66
Hypercortisolemia and depression. Psychosom Med (2005) 1.60
Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry (2001) 1.53
Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci (2004) 1.53
Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry (1988) 1.53
Requirement of FoxD3-class signaling for neural crest determination in Xenopus. Development (2001) 1.50
Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology (2002) 1.45
Executive functions and updating of the contents of working memory in unipolar depression. J Psychiatr Res (2004) 1.41
Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses. J Neurosci (2003) 1.39
Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci (2004) 1.26
Effects of cyclic adenosine monophosphate response element binding protein overexpression in the basolateral amygdala on behavioral models of depression and anxiety. Biol Psychiatry (2004) 1.25
Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics. Psychopharmacol Bull (2001) 1.22
Biochemical adaptations in the mesolimbic dopamine system in response to repeated stress. Neuropsychopharmacology (1996) 1.18
Getting closer to affective disorders: the role of CRH receptor systems. Trends Mol Med (2004) 1.13
Identification of FOXC1 as a TGF-beta1 responsive gene and its involvement in negative regulation of cell growth. Genomics (2002) 1.10
Urocortin III, a brain neuropeptide of the corticotropin-releasing hormone family: modulation by stress and attenuation of some anxiety-like behaviours. J Neuroendocrinol (2004) 1.05
Protein kinase A in postmortem brain of depressed suicide victims: altered expression of specific regulatory and catalytic subunits. Biol Psychiatry (2004) 0.99
GABAergic hypotheses of anxiety and depression: focus on GABA-B receptors. Drugs Today (Barc) (2005) 0.99
A simplified method for combined immunohistochemistry and in-situ hybridization in fresh-frozen, cryocut mouse brain sections. Brain Res Brain Res Protoc (2002) 0.99
Multiple sclerosis, interferon beta-1b and depression A prospective investigation. J Neurol (2002) 0.96
Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler (2001) 0.94
Individual differences in spatial memory among aged rats are related to hippocampal PKCgamma immunoreactivity. Hippocampus (2002) 0.94
Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br J Pharmacol (2006) 0.90
Cannabinoid control of motor function at the basal ganglia. Handb Exp Pharmacol (2005) 0.89
Depression in multiple sclerosis associated with interferon beta-1a (Rebif). Can J Psychiatry (2002) 0.84
An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr Res (2002) 0.83
Spatial memory in aged rats is related to PKCgamma-dependent G-protein coupling of the M1 receptor. Neurobiol Aging (2005) 0.83
Impaired passive avoidance acquisition in Wistar rats after restraint/cold stress and/or stresscopin administration. Gen Physiol Biophys (2003) 0.79
Translocation of protein kinase Cgamma occurs during the early phase of acquisition of food rewarded spatial learning. Behav Neurosci (1998) 0.78
Spatial learning in rats is impaired by microinfusions of protein kinase C-gamma antisense oligodeoxynucleotide within the nucleus accumbens. Neurobiol Learn Mem (2004) 0.78
Plasma levels of cyclic GMP, immune parameters and depressive status during interferon therapy. A prospective study in Japan. Neuropsychobiology (1997) 0.77
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (2010) 10.97
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
The many faces of CREB. Trends Neurosci (2005) 5.58
Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science (2006) 5.31
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci (2002) 5.17
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med (2009) 4.71
Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology (2007) 4.38
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry (2011) 3.62
Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol (2012) 3.62
Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell (2007) 3.60
A negative regulator of MAP kinase causes depressive behavior. Nat Med (2010) 3.52
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 3.35
The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol (2007) 3.32
IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A (2008) 3.19
Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med (2008) 3.15
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis (2009) 3.08
Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus (2006) 3.02
Aortic valve surgery after previous coronary artery bypass grafting with functioning internal mammary artery grafts. Ann Thorac Surg (2002) 2.88
Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med (2010) 2.86
Preclinical models: status of basic research in depression. Biol Psychiatry (2002) 2.76
Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology (2003) 2.75
Results and predictors of early and late outcomes of coronary artery bypass graft surgery in octogenarians. J Cardiothorac Vasc Anesth (2007) 2.73
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry (2004) 2.54
Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology (2008) 2.43
EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. J Am Soc Echocardiogr (2012) 2.41
Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. Neuron (2003) 2.41
Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology (2010) 2.37
Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements. J Immunol (2010) 2.36
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med (2007) 2.32
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry (2006) 2.28
Induction of deltaFosB in reward-related brain structures after chronic stress. J Neurosci (2004) 2.27
Integrated thoracic residency program applicants: the best and the brightest? Ann Thorac Surg (2011) 2.22
VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci U S A (2007) 2.22
Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J Neurosci (2002) 2.21
Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. Proc Natl Acad Sci U S A (2010) 2.19
Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci U S A (2010) 2.17
Bilateral internal mammary artery grafts, mortality and morbidity: an analysis of 1 526 360 coronary bypass operations. Heart (2013) 2.15
Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry (2008) 2.14
The role of hemochromatosis susceptibility gene mutations in protecting against iron deficiency in celiac disease. Gastroenterology (2002) 2.12
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol (2005) 2.10
Management of systolic anterior motion after mitral valve repair: an algorithm. J Thorac Cardiovasc Surg (2012) 2.07
Guidelines for reporting mortality and morbidity after cardiac valve interventions. Ann Thorac Surg (2008) 2.04
Cardiac myxoma: preoperative diagnosis using a multimodal imaging approach and surgical outcome in a large contemporary series. Interact Cardiovasc Thorac Surg (2007) 2.03
Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiatry (2007) 2.01
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med (2012) 1.97
Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: genes or environment? Pharmacogenomics (2013) 1.97
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med (2011) 1.97
Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem (2004) 1.96
A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry (2006) 1.95
Gene profile of electroconvulsive seizures: induction of neurotrophic and angiogenic factors. J Neurosci (2003) 1.95
CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. J Hepatol (2012) 1.95
Chronic unpredictable stress decreases cell proliferation in the cerebral cortex of the adult rat. Biol Psychiatry (2007) 1.94
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry (2013) 1.92
Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One (2009) 1.91
Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci (2002) 1.89
Voluntary exercise produces antidepressant and anxiolytic behavioral effects in mice. Brain Res (2008) 1.84
Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron (2003) 1.84
Human MAIT and CD8αα cells develop from a pool of type-17 precommitted CD8+ T cells. Blood (2011) 1.83
Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease. Hepatology (2010) 1.82
Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology (2010) 1.81
GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology (2006) 1.80
Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res (2010) 1.79
Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation (2009) 1.78
A propensity score-adjusted retrospective comparison of early and mid-term results of mitral valve repair versus replacement in octogenarians. Eur Heart J (2010) 1.78
Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry (2004) 1.77
Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry (2011) 1.77
The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.76
Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg (2008) 1.76
A three-dimensional ring annuloplasty for the treatment of tricuspid regurgitation. Ann Thorac Surg (2006) 1.75
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr (2009) 1.73
Antidepressant actions of the exercise-regulated gene VGF. Nat Med (2007) 1.69
The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog (2013) 1.67
TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting. Biol Psychiatry (2006) 1.67
Antidepressants and neuroplasticity. Bipolar Disord (2002) 1.66
The intraoperative "ink test": a novel assessment tool in mitral valve repair. J Thorac Cardiovasc Surg (2007) 1.64
Convergent antibody signatures in human dengue. Cell Host Microbe (2013) 1.64
Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol (2010) 1.61
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry (2007) 1.60
Incidence, topography, predictors and long-term survival after stroke in patients undergoing coronary artery bypass grafting. Ann Thorac Surg (2008) 1.60
Primary sclerosing cholangitis. Lancet (2013) 1.59
Regional and cellular mapping of cAMP response element-mediated transcription during naltrexone-precipitated morphine withdrawal. J Neurosci (2002) 1.58
Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med (2005) 1.57
Vascular adhesion protein-1 mediates adhesion and transmigration of lymphocytes on human hepatic endothelial cells. J Immunol (2002) 1.55
Inverted left atrial appendage. J Am Coll Cardiol (2009) 1.55
Predictors and early and late outcomes of dialysis-dependent patients in contemporary cardiac surgery. J Cardiothorac Vasc Anesth (2008) 1.54
Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry (2008) 1.54